BBIO
NASDAQ
US
BridgeBio Pharma, Inc. - Common Stock
$73.15
▼ $-1.30
(-1.75%)
Vol 1.2M
6
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$14.7B
ROE
-206.7%
Margin
-225.3%
D/E
827.29
Beta
1.13
52W
$27–$78
Wall Street Consensus
29 analysts · Apr 20269
Strong Buy
19
Buy
1
Hold
0
Sell
0
Strong Sell
96.6%
Buy Rating
Price Chart
Similar Stocks
RVMD
Revolution Medicines Inc
$15.4B
MRNA
Moderna Inc
$11.5B
INCY
Incyte Corp
P/E 16.3
$19.4B
SMMT
Summit Therapeutics Inc
$13.0B
NBIX
Neurocrine Biosciences Inc
P/E 33.0
$14.1B
MDGL
Madrigal Pharmaceuticals Inc
$13.2B
IONS
Ionis Pharmaceuticals Inc
$12.8B
EXEL
Exelixis Inc
P/E 17.3
$11.8B
BMRN
BioMarin Pharmaceutical Inc
P/E 21.9
$11.4B
Earnings
Beat rate: 25.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.76 | $-1.00 | $-0.24 |
| Sep 2025 | $-0.91 | $-0.95 | $-0.04 |
| Jun 2025 | $-0.86 | $-0.95 | $-0.09 |
| Mar 2025 | $-0.94 | $-0.88 | +$0.06 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $5.9M | $116.6M | $110.6M | $120.7M | $154.2M |
| Net Income | — | -$265.1M | -$167.4M | -$181.9M | -$182.7M | -$192.9M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -206.7% | -206.7% | -206.7% | -206.7% | -206.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -164.5% | -329.2% | -329.2% | -329.2% | -225.3% | -225.3% |
| Gross Margin | 96.7% | 96.2% | 96.2% | 96.2% | 95.8% | 95.8% |
| D/E Ratio | — | 827.29 | 827.29 | 827.29 | 827.29 | 827.29 |
| Current Ratio | 5.19 | 5.19 | 5.19 | 5.19 | 3.88 | 3.88 |
Key Ratios
ROA (TTM)
-82.2%
P/S (TTM)
41.67
P/B
150.7
EPS (TTM)
$-4.19
CF/Share
$-3.94
Rev Growth 3Y
+47.1%
52W High
$78.44
52W Low
$27.23
$27.23
52-Week Range
$78.44
Financial Health
Free Cash Flow
-$56.5M
Net Debt
$1.3B
Cash
$570.1M
Total Debt
$1.9B
As of Dec 31, 2025
How does BBIO compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
BBIO valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
41.7
▲
224%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
150.7
▲
6027%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
BBIO profitability vs Biotechnology peers
ROE
-206.7%
▼
207%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-225.3%
▲
21%
above
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
95.8%
▲
22%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-82.2%
▼
76%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
BBIO financial health vs Biotechnology peers
D/E ratio
827.3
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
3.9
▼
13%
below
peers
(4.4)
vs Peers
vs Industry
In line
Beta
1.1
▲
16%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
BBIO fundamentals radar
BBIO
Peer median
Industry
BBIO profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
BBIO vs peers: key metrics
Latest News
No related news yet